Q-Med AB invites to year-end report conference call

Q-Med AB invites to year-end report conference call

Time:  Friday, February 13, 2009 at 10.00 a.m. CET.

To join the conference:  
Swedish dial in number: + 46 (0)8 505 201 10
UK dial in number: +44 (0)20 7162 0077

Q-Med participants: 	
Bengt Ågerup, CEO
Alexander Kotsinas, CFO
Madelene Sandgren, Director Investor Relations and Corporate Communications

The press release for Q-Med AB's end-year report will be released approximately 
07.30 on February 13, 2009.

The slide presentation will be available at:
www.q-med.com/Investors/Presentations

A recorded version of the presentation will be available for seven working days
on 
tel: Sweden +46 (0)8 505 203 33 or UK +44 (0)20 7031 4064, access code: 82 54
36.
Financial information from Q-Med during Year 2009

28 April	 Interim Report January - March 2009
29 April	 Annual General Meeting
23 July 	Interim Report January - June 2009 
23 October Interim Report January - September 2009

Queries should be addressed to: 
Madelene Sandgren, Director Investor Relations and Corporate Communications,
Tel: + 46 (0)70 974 90 15

Q-Med AB is a rapidly growing and profitable biotechnology/medical device
company. The company develops, manufactures, markets, and sells primarily
medical implants. The majority of the products are based on the company's
patented technology, NASHA™, for the production of stabilized non-animal
hyaluronic acid. The product portfolio today contains: Restylane® for filling
lines and folds, contouring and creating volume in the face, Macrolane™ for body
contouring, Durolane™ for the treatment of osteoarthritis of the hip and knee
joints, Deflux® for the treatment of vesicoureteral reflux, VUR, (a malformation
of the urinary bladder) in children, and Solesta™ for the treatment of fecal
incontinence. Sales are made through the company's own subsidiaries or
distributors in over 70 countries. Q Med today has just over 700 coworkers, with
close to 500 at the company's head office and production facility in Uppsala,
Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in
Stockholm.